Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Richard Cathomas is a leading figure in uro-oncology, whose work has fundamentally shaped the global standard of care for bladder cancer. His primary research focuses on muscle-invasive and metastatic bladder cancer, with a particular emphasis on optimizing perioperative treatment strategies. Dr. Cathomas is best known for his pivotal role in authoring the European Association of Urology (EAU) Guidelines on Muscle-invasive and Metastatic Bladder Cancer, with the 2020 edition alone amassing over 2,100 citations, making it an indispensable resource for clinicians worldwide. His impact extends beyond guideline development into groundbreaking clinical trials. Notably, he led the SAKK 06/17 phase II trial, which investigated perioperative chemoimmunotherapy with durvalumab and cisplatin/gemcitabine for operable muscle-invasive urothelial carcinoma. This work is critical in the ongoing effort to integrate immune checkpoint inhibitors into the neoadjuvant setting, aiming to reduce the high relapse rates seen with standard chemotherapy. Through his authoritative guidelines and innovative trial designs, Dr. Cathomas continues to drive the evolution of treatment for one of the most challenging urological malignancies.